Liminatus Pharma Regains Compliance With Nasdaq’s Minimum Bid Price Rule

Liminatus Pharma has regained compliance with Nasdaq's minimum bid price rule after its common stock closed above $1.00 per share for 13 consecutive trading days, from August 21, 2026, to September 9, 2026. Nasdaq has confirmed that the matter is now closed.